Evaluation of the benefit of the addition of 1% topical luliconazole versus topical bland emollient to the systemic itraconazole therapy for the management of disseminated dermatophytosis: A randomised control trial

• Published in: Mycoses Vol. 67; no. 1; pp. e13681 - n/a
• Main Authors: Rana, Deval K., Shah, Tithi S., Rohit, Mansi H., Patel, Nayankumar H., Khadela, Avinash D., Oza, Yaksh P., Padhiyar, Jigna K.
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.01.2024
• Subjects: Antifungal Agents - therapeutic use; cost‐effectiveness; cure rate; Dermatomycosis; dermatophytosis; Drug abuse; Emollients - therapeutic use; Humans; Imidazoles; incremental cost‐effectiveness ratio; Itraconazole; Itraconazole - therapeutic use; luliconazole; Patients; Recurrence; Skin care products; Tinea - drug therapy; India; cost-effectiveness; incremental cost-effectiveness ratio; luliconazole; itraconazole; cure rate; dermatophytosis
• ISSN: 0933-7407; 1439-0507
• DOI: 10.1111/myc.13681

Background The present epidemic of dermatophytosis in India is marked by an increase in chronic, recurrent and disseminated cases. A combination of oral itraconazole and topical luliconazole is being increasingly utilised by dermatologists in India. The superiority of this combination is not supported by robust clinical trial data. Objective We conducted this randomised, open‐label, two arms, parallel assignment intervention trial between November 2022 and May 2023 to determine the superiority of topical 1% Luliconazole over bland emollient as adjuvant to systemic Itraconazole therapy in the management of dermatophytosis. Method In this study, 135 patients of either sex were randomised to two study cohorts. Major exclusions being concomitant medical illness, use of concomitant medication and substance abuse. Participants were randomly assigned to receive topical bland emollient, (Cohort I, n = 67) or topical luliconazole, (Cohort II, n = 68). Both cohorts received oral itraconazole 200 mg/day (100 mg BID) and levocetirizine 5 mg twice a day as a systemic regime. Clinical and mycological cure at the end of 6 weeks and clinical relapse among cure patients during 10‐week follow‐up were observed. Results The cure rates for Cohorts I and II at 6 weeks were 50 (74.62%) and 56 (82.35%), (p = .46), respectively. During the 4‐week follow‐up period, clinical relapses were observed in 16 (32%) of the 50 patients in Cohort I and 12 (21.43%) of the 56 patients in Cohort II (p = .18). Luliconazole cohort shows a significantly higher medical cost (p < .05). Conclusion Our study shows a similar cure rate and relapse rate for patients receiving topical Luliconazole versus topical bland emollient as an adjuvant to the systemic itraconazole regime.